The Breast Screening Challenge Is Not Getting Women There. It Is Keeping Them There.

Breast screening is often discussed as an access problem. And it is. But access is only the first step.

The deeper challenge is continuity: making sure women do not simply enter the screening pathway once, but return again and again at the appropriate interval. In organized breast screening, success is not a single mammogram. It is a repeated cycle — invitation, appointment, exam, result, recall if needed, diagnostic assessment if needed, return to routine screening, repeat.

When that cycle works, screening can do what decades of international evidence says it should: detect cancer earlier, support timely follow-up, and reduce breast cancer mortality in the women it reaches. When that cycle breaks, prevention weakens.

This is why the most important question may no longer be only: How do we get women into screening? It may be: How do we make sure they come back?

---

COVID Exposed the Difference Between Access and Resilience

The COVID-19 pandemic created a global interruption point for breast screening. A rapid review published in eLife found broad reductions in breast screening participation or volume during 2020, but the size of the disruption varied substantially by country and healthcare setting. The review included 26 studies across 13 countries and emphasized the importance of monitoring recovery among disadvantaged groups.¹

That variation matters. It tells us that screening systems were not affected equally. Some programs had the infrastructure to absorb disruption, maintain invitations, restart quickly, and track who had been missed. Others struggled to recover participation, and in many places the women most likely to be left behind were those already facing social, economic, geographic, or language barriers.

That is the central lesson: screening recovery is not only about capacity. It is about system design.

The Countries Doing Well Have Something in Common

There is no perfect global ranking. Countries differ in age ranges, reporting methods, screening intervals, and whether they measure invitations, attendance, coverage, or self-reported mammography.

But when we compare data from major international health organizations, global cancer-screening repositories, and national breast screening programs, one pattern becomes clear: the strongest performers are not relying on awareness alone. They have built systems that make returning to screening the default.

The World Health Organization makes the underlying point plainly: in well-resourced settings, an organized, population-based program — rather than opportunistic screening offered case by case — is what allows a country to use resources efficiently and distribute access equitably. The structure is not bureaucratic overhead. It is the mechanism.¹²

The Organisation for Economic Co-operation and Development reports that Sweden reached approximately 83% breast screening coverage among women aged 50–69 in its latest comparison, against an OECD average near 55%. Denmark, Finland, Portugal, and Sweden all screened at least 80% of eligible women in that age band, while the lowest-performing countries remained under 30%.² Eurostat similarly reports that in 2023, Denmark, Sweden, and Finland were the EU countries where at least 80% of eligible women had been screened within recent years, while the lowest national rate in the EU — in Greece — was 14.5%.³

Finland provides a particularly useful example of how continuity can be measured. In 2021, the Finnish breast cancer screening program sent more than 356,000 invitations, participation reached 82%, and 2.8% of participants were referred for confirmatory examination. The program detected 1,755 breast cancers and carcinomas in situ, equal to approximately six cases per 1,000 women screened.⁴

Norway's BreastScreen Norway program illustrates the value of public reporting. The program publishes key figures — invitations, attendance rates, additional examinations, and cancer detections — making it possible to evaluate not only whether screening occurred, but whether the pathway functioned.^5,6

These countries are not identical. Their healthcare systems, geography, governance, and reporting structures differ. But the foundations are remarkably similar.

The Counter-Intuitive Part: The Appointment Is Not the Finish Line

Here is the assumption almost everyone makes: if you can just get a woman an appointment, she will come. The data says otherwise.

Spain runs an organized, appointment-based program, and yet early detection has been slipping for years. A 2026 analysis of Spanish Ministry of Health data found that among women aged 50 to 69, breast screening participation fell from 81.5% in 2017 to 68%, leaving roughly one in three women not screened on schedule. The decline was steepest in the most disadvantaged groups, where coverage dropped to between 60% and 62%. The appointment existed. The system functioned. Women still fell out of the cycle.⁷

Now consider a quieter, and more uncomfortable, finding from the United States. In a Breast Cancer Surveillance Consortium study of more than 3.5 million mammograms published in 2024, about 77% of women returned for their next routine screen after a normal result. After a false-positive result that required short-interval follow-up, only about 61% came back. After one that led to a biopsy recommendation, about 67% returned. After two consecutive false alarms, just 56% returned. And the women least likely to come back included Asian, Hispanic, and Latina women — which means the recall experience can widen the very gaps screening is meant to close.⁸

The mechanism designed to catch cancer earlier can, when it misfires, push a woman out of the pathway entirely.

This is why the strongest programs treat recall as something to be measured and minimized, not simply tolerated. Finland refers only about 2.8% of participants for confirmatory examination. BreastScreen Norway expects additional examinations in roughly 3% of those screened. BreastScreen Australia reports its recall-to-assessment rates separately for first and subsequent screens — about 11% at a first screen and about 4% at later screens in 2023 — so the program can see exactly where unnecessary callbacks cluster.⁹ Every avoidable recall is not only a cost and a source of anxiety. It is a chance to lose a woman who might not come back.

The leak points are not only at the front door. They appear after the invitation, after the booked appointment, after the scare. Continuity has to be engineered across the entire pathway, not just at the moment of entry.

The Formula: Five Things Successful Systems Do Well

1. They Define the Eligible Population

A strong screening program begins by knowing who should be invited. Without a defined eligible population, it is difficult to know who is due, who was invited, who attended, who missed the appointment, who needs diagnostic follow-up, and who should return to routine screening.

The International Agency for Research on Cancer created CanScreen5 to compare how countries organize and monitor breast, cervical, and colorectal cancer screening programs. CanScreen5 reports screening-program status and performance using a harmonized set of criteria and indicators, with data quality validation before publication.¹⁰

Takeaway: Awareness campaigns can generate interest, but registries create accountability.

2. They Invite Women Back Automatically

The best systems are active, not passive. They do not simply make screening available and wait for women to find their way back. They identify who is due and issue an invitation.

This is the difference between "Screening is available" and "You are due. Here is your pathway back."

That shift matters because life is complicated. Women miss screening for many reasons: caregiving responsibilities, work schedules, transportation, fear, misunderstanding, competing health needs, cost concerns, language barriers, and simple loss of momentum after a disruption. An automatic invitation system reduces the dependence on memory, motivation, and individual navigation.

Takeaway: Continuity improves when the system carries part of the burden.

3. They Reduce Appointment Friction

The most effective programs do not only tell women to schedule. They make scheduling easier. The European Commission Initiative on Breast Cancer favors a letter with a fixed appointment over a letter alone for inviting women to subsequent breast screening rounds.¹¹

This is a small operational detail with large implications. A fixed or suggested appointment changes screening from something a woman must initiate into something already placed on the calendar. It creates a default path. For many women, that can be the difference between returning on time and falling out of the cycle.

Takeaway: Friction is a clinical quality issue. Every extra step can become a dropout point.

4. They Track the Full Pathway, Not Just the Mammogram

Participation is important, but it is not enough. A complete screening program should be able to monitor the entire pathway: invitation, attendance, screening result, recall, diagnostic assessment, cancer detection, return to routine screening.

A woman can be lost at any of these points. She may never receive the invitation. She may receive it but not attend. She may attend screening but not complete diagnostic assessment after an abnormal result. Or she may complete one round and then fall out before the next.

Programs such as Finland's and Norway's publicly report multiple parts of the pathway, including invitations, participation, additional examinations, and cancer detection.^4,6

Takeaway: What is not measured is easily missed.

5. They Treat Equity as a Quality Metric

Average participation can hide serious gaps. Across Europe, lower breast screening participation is associated with social and structural factors such as education, income, and rurality. The Finnish program shows how visible this becomes once the data is stratified: in 2021, participation among women with a tertiary education was about 86%, compared with roughly 69% among women whose highest level of education was primary.⁴

In the United States, CDC data show that mammography use decreases as adverse social determinants of health and health-related social needs increase; barriers include cost, lack of transportation, lack of insurance, social isolation, and lack of a usual source of care.¹³

A national average can look acceptable while specific groups are being left behind. The next generation of screening quality should ask two questions together: How many women returned? And: Which women did not return — and why?

Takeaway: Equity is not separate from quality. It is one of the clearest tests of quality.

What Breast Imaging Programs Can Learn From High-Performing Countries

The lesson from high-performing countries is not that every system can copy Denmark, Sweden, Finland, or Norway exactly. Healthcare financing, geography, workforce capacity, digital infrastructure, patient culture, privacy rules, and screening guidelines differ around the world. But the operating principles can travel.

For breast centers, health systems, payers, public-health agencies, and technology partners, the practical questions become:

• Do we know who is due? Not just who came in last year, but who should be returning now.
• Do we know who missed? Missed screening should not disappear into silence.
• Do we know who needs diagnostic follow-up? Recall without completed assessment is an unfinished pathway.
• Do we know who has fallen out of the interval? A delayed return may not look urgent on a daily schedule, but across a population it becomes a prevention gap.
• Do we know which groups are being left behind? If screening continuity is lower by language, geography, income, insurance status, transportation access, disability, or age group, the program needs to see that clearly.

This is where technology and workflow design matter — not as an abstract digital transformation project, but as a practical continuity engine. A strong continuity system should help programs identify eligible women, issue invitations, support reminders, monitor missed appointments, close abnormal-result loops, measure follow-up completion, and report equity gaps.

The goal is not more data for its own sake. The goal is fewer women lost between steps.

The Real Opportunity

The countries doing well are not succeeding because of one magic intervention. They are succeeding because they have built continuity systems. They know who is eligible. They invite women back. They reduce scheduling friction. They track the pathway. They measure gaps. They make screening easier to continue.

That is the opportunity for breast imaging globally. Screening success should not be measured only by program availability. It should be measured by whether women can stay connected to the screening pathway over time.

This is especially important after COVID. The pandemic did not create every weakness in screening systems, but it exposed them. It showed which programs could recover, which populations were more vulnerable to falling out of the cycle, and why return may be one of the most important words in modern breast screening.

The Message Is Simple

Breast screening does not save lives as a one-time event. It works best when women can return at the right interval, receive timely follow-up when needed, and remain visible to the system over time.

The next frontier is not simply awareness. It is not simply access. It is not even simply capacity.

The next frontier is continuity.

Because the future of breast screening will not be defined only by how many women start. It will be defined by how many women come back.

References

1. Lee R, Xu W, Dozier M, McQuillan R, Theodoratou E, Figueroa J; UNCOVER and the International Partnership for Resilience in Cancer Systems Breast Cancer Working Group. A rapid review of COVID-19's global impact on breast cancer screening participation rates and volumes from January to December 2020. eLife. 2023;12:e85680. doi:10.7554/eLife.85680.
2. Organisation for Economic Co-operation and Development. Cancer screening. In: Health at a Glance 2025: OECD Indicators. OECD Publishing; 2025. doi:10.1787/8f9e3f98-en. Accessed June 28, 2026.
3. Eurostat. Cancer screening statistics. Statistics Explained. Data extracted 2025. Accessed June 28, 2026.
4. Finnish Cancer Registry. Breast cancer screening programme: annual screening statistics, 2020–2024. Finnish Cancer Registry; updated May 21, 2026. Accessed June 28, 2026.
5. Norwegian Institute of Public Health, Cancer Registry of Norway. BreastScreen Norway. Accessed June 28, 2026.
6. Norwegian Institute of Public Health, Cancer Registry of Norway. Key figures for BreastScreen Norway. Updated May 6, 2025. Accessed June 28, 2026.
7. Sánchez J. 32% of women in Spain miss breast screening despite receiving an appointment from the system. APD Notícies. June 26, 2026. Accessed June 28, 2026. (Reporting Spanish Ministry of Health data.)
8. Miglioretti DL, et al. Association between false-positive results and return to screening mammography in the Breast Cancer Surveillance Consortium cohort. Ann Intern Med. 2024;177:1297–1307. doi:10.7326/M24-0123.
9. Australian Institute of Health and Welfare. BreastScreen Australia Monitoring Report 2025. AIHW; 2025. Accessed June 28, 2026.
10. Zhang L, Mosquera I, Lucas E, Rol ML, Carvalho AL, Basu P; CanScreen5 Collaborators. CanScreen5, a global repository for breast, cervical and colorectal cancer screening programs. Nat Med. 2023;29(5):1135–1145. doi:10.1038/s41591-023-02315-6.
11. European Commission Initiative on Breast Cancer. European guidelines on breast cancer screening and diagnosis: recommendations. Accessed June 28, 2026.
12. World Health Organization. WHO Position Paper on Mammography Screening. World Health Organization; 2014. Accessed June 28, 2026.
13. Miller JW, King JA, Trivers KF, et al. Vital Signs: mammography use and association with social determinants of health and health-related social needs among women — United States, 2022. MMWR Morb Mortal Wkly Rep. 2024;73(15):351–357. doi:10.15585/mmwr.mm7315e1.